<DOC>
	<DOCNO>NCT00812968</DOCNO>
	<brief_summary>The purpose clinical experience study determine whether CC-5013 safe effective ( include study process drug absorb , distribute , metabolize , eliminate body [ pharmacokinetics ] ) Japanese subject low- intermediate-1-risk MDS ( IPSS risk category ) associate deletion 5 ( q31-33 ) abnormality symptomatic anemia .</brief_summary>
	<brief_title>Study CC-5013 Evaluate Safety , Pharmacokinetics Effectiveness Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With Del ( 5 ) ( q31-33 ) Abnormality .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Age ≥ 20 year time signing informed consent form . Must able adhere study visit schedule protocol requirement . Diagnosis Myelodysplastic Syndrome ( MDS ) meet International Prognostic Scoring System ( IPSS ) criteria low intermediate1risk disease associate deletion 5 ( q3133 ) abnormality Symptomatic anemia secondary MDS define : Untransfused Hb level &lt; 10.0 g/dL Functional Assessment Cancer Therapy ( FACT ) anemia subscale score ≤ 74 Transfusion dependent anemia Pregnant lactating female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study . Prior therapy lenalidomide . Patients follow laboratory abnormality within 14 day start study drug : Absolute Neutrophil Count ( ANC ) &lt; 750 cells/μL ( 0.75 x 10^9/L ) Platelet count &lt; 50,000/μL ( 50x10^9/L ) Serum creatinine &gt; 2.5 mg/dL Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &gt; 3.0 x Upper Limit Normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>